Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

Summary

The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified classification criteria according to Kahn (2003), with the ineffectiveness of standard treatment (patient's global assessment of the disease on the VAS scale greater than or equal to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.

Timeline

Start

2024-09-04

Primary completion

2028-10-18

Completion

2028-10-18

Drugs

Indications